pathology, much of which we can prevent: hypertension, heart failure and ischaemic heart disease. Even if these diseases cannot be prevented they can be vigorously treated, and the prevalence of atrial fibrillation will fall.
Treatment with statins, antihypertensive therapy, angiotensin receptor blockade (ARB), angiotensin converting enzyme inhibitors (ACE-Is) and omega-3 fatty acids all seem to provide effective therapy for atrial fibrillation, perhaps over and above any effect related to the treatment of underlying heart disease. For example, an anti-inflammatory mechanism has been proposed for statins, 5 and an anti-fibrotic mechanism for ARBs and ACE-I's. 6 Thus there may already be some treatments for AF that are not due to other underlying heart disease.
Membrane ion channel antagonists such as Kv1.5 blockers that are relatively specific for the atrial myocardium are now being developed. 7 They may terminate or prevent AF without provoking ventricular proarrhythmia, but their efficacy is uncertain. Aplethora of completely new antiarrhythmic effects 8, 9 are now envisioned: connexin modulation, stretch receptor antagonism,blockade of the sodium calcium exchanger, sodium hydrogen exchange block, late sodium channel inhibition. One or more of these effects may turn out to be 'just the job' but if not, others will emerge.
The epidemic of atrial fibrillation and its complications will eventually subside, not today but sometime soon. 
